CLSD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLSD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-10), Clearside Biomedical's intrinsic value calculated from the Discounted Cash Flow model is $-6.26.
Note: Discounted Cash Flow model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's predictability rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.
Clearside Biomedical's Predictability Rank is 1-Star. Thus, this page is only used for demonstration purposes and the DCF related results in the screener and portfolio will appear as zero.
Margin of Safety (FCF Based) using Discounted Cash Flow model for Clearside Biomedical is N/A.
The industry rank for Clearside Biomedical's Intrinsic Value: DCF (FCF Based) or its related term are showing as below:
The historical data trend for Clearside Biomedical's Intrinsic Value: DCF (FCF Based) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Intrinsic Value: DCF (FCF Based) | Get a 7-Day Free Trial | - | - | - | - | - |
Clearside Biomedical Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Intrinsic Value: DCF (FCF Based) | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Clearside Biomedical's Price-to-DCF (FCF Based), along with its competitors' market caps and Price-to-DCF (FCF Based) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Price-to-DCF (FCF Based) distribution charts can be found below:
* The bar in red indicates where Clearside Biomedical's Price-to-DCF (FCF Based) falls into.
This is the intrinsic value calculated from the Discounted Cash Flow model with default parameters. In a discounted cash flow model, the future cash flow is estimated based on a cash flow growth rate and a discount rate. The cash flow of the future is discounted to its current value at the discount rate. All of the discounted future cash flow is added together to get the current intrinsic value of the company.
Usually a two-stage model is used when calculating a stock's intrinsic value using a discounted cash flow model. The first stage is called the growth stage; the second is called the terminal stage. In the growth stage the company grows at a faster rate. Because it cannot grow at that rate forever, a lower rate is used for the terminal stage.
GuruFocus DCF calculator is a two-stage model. The default values are defined as:
1. Discount Rate: d = 11%
A reasonable discount rate assumption should be at least the long term average return of the stock market, which can be estimated from risk free rate plus risk premium of stock market. GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate and rounded up to the nearest integer. It is updated daily. The current risk-free rate is 4.45%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default. Then we added a risk premium of 6% to get the estimated discount rate. Some investors use their expected rate of return, which is also reasonable. A typical discount rate can be anywhere between 6% - 20%.
2. Growth Rate in the growth stage: g1 = 13.20%
The Growth Rate in the growth stage is initially set as the default 10-Year FCF Growth Rate (Per Share). In cases where the 10-year growth rate is unavailable, it defaults to using the 5-Year FCF Growth Rate (Per Share). If both the 10-year and 5-year growth rates are unavailable, the system defaults to the 3-Year FCF Growth Rate (Per Share).
However, it's important to note that there is a growth rate range. If the calculated growth rate exceeds 20%, it will be capped at 20%. Conversely, if the calculated growth rate falls below 5%, it will be adjusted to 5% to maintain a reasonable range.
=>
Clearside Biomedical's average Free Cash Flow Growth Rate in the past
10 years was 13.20%,
which is between 5% and 20%. => GuruFocus defaults => Growth Rate: 13.20%
3. Years of Growth Stage: y1 = 10
4. Terminal Growth Rate: g2 = 4%
5. Years of Terminal Growth: y2 = 10
6. Free Cash Flow per Share: fcf = $-0.316.
However, GuruFocus DCF calculator is actually a Discounted Earnings calculator, the EPS without NRI is used as the default. The reason we are doing this is we found that historically stock prices are more correlated with earnings than free cash flow.
All of the default settings can be changed and the results are calculated automatically.
Clearside Biomedical's Intrinsic Value: DCF (FCF Based) for today is calculated as
Intrinsic Value: DCF (FCF Based) | = | Free Cash Flow per Share | * | {[(1+g1)/(1+d) | + | (1+g1)^2/(1+d)^2 | + | ... | + | (1+g1)^10/(1+d)^10] |
+ | (1+g1)^10/(1+d)^10 | * | [(1+g2)/(1+d) | + | (1+g2)^2/(1+d)^2 | + | ... | + | (1+g2)^10/(1+d)^10]} |
set x = (1+g1)/(1+d) = (1+0.132)/(1+0.11) = 1.0198198198198
and y = (1+g2)/(1+d) = (1+0.04)/(1+0.11) = 0.93693693693694
Intrinsic Value: DCF (FCF Based) | = | Free Cash Flow per Share | * | {[x | + | x^2 | + | ... | + | x^10] | + | x^10 | * | [y | + | y^2 | + | ... | + | y^10]} |
= | Free Cash Flow per Share | * | [x | * | (1-x^10) | / | (1-x) | + | x^10 | * | y | * | (1-y^10) | / | (1-y)] | |||||
= | -0.316 | * | 19.8115 | |||||||||||||||||
= | -6.26 |
Margin of Safety (FCF Based) | = | (Intrinsic Value: DCF (FCF Based) | - | Current Price) | / | Intrinsic Value: DCF (FCF Based) |
= | (-6.26 | - | 1.22) | / | -6.26 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (NAS:CLSD) Intrinsic Value: DCF (FCF Based) Explanation
Unlike valuation methods such as Net Current Asset Value, Tangible Book per Share, Graham Number, Median PS Value etc, discounted Cash Flow model evaluates the companies based on their future earnings power instead of their assets.
Be Aware
What you need to know about the DCF model:
1. The DCF model evaluates a company based on its future earnings powerYou can screen for stocks that trade below their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) with the GuruFocus All-in-One Screener. Companies with a high Predictability Rank that trade at a discount to their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) can be found in the screen of Undervalued Predictable Companies.
Thank you for viewing the detailed overview of Clearside Biomedical's Intrinsic Value: DCF (FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles A. Deignan | officer: Chief Financial Officer | C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005 |
George M Lasezkay | director | 1301 SECOND AVE., SUITE 4200, SEATTLE WA 98101 |
Bradford T Whitmore | 10 percent owner | 5215 OLD ORCHARD ROAD, SUITE 620, SKOKIE IL 60077 |
Nancy J Hutson | director | 64 MONTAUK AVENUE, STONINGTON CT 06378 |
Clay Thorp | director, 10 percent owner | C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701 |
Thomas Ciulla | officer: Chief Medical Officer | C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA GA 30005 |
Benjamin R Yerxa | director | INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466 |
William D. Humphries | director | C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044 |
Jeffrey L Edwards | director | 2525 DUPONT DR, IRVINE CA 92612 |
Daniel H. White | director, officer: President and CEO | C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005 |
Gerald D. Cagle | director | 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921 |
Brion S. Raymond | officer: Chief Commercial Officer | C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005 |
Christy L Shaffer | director | INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466 |
Hatteras Venture Advisors Iv Sbic, Llc | 10 percent owner | 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701 |
Hatteras Venture Advisors Iii, Llc | 10 percent owner | 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701 |
From GuruFocus
By Marketwired • 08-01-2023
By sperokesalga sperokesalga • 04-19-2023
By Marketwired • 09-19-2023
By Value_Insider Value_Insider • 11-22-2022
By sperokesalga sperokesalga • 04-18-2023
By sperokesalga sperokesalga • 02-21-2023
By sperokesalga sperokesalga • 04-12-2023
By sperokesalga sperokesalga • 05-11-2023
By sperokesalga sperokesalga • 05-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.